Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Details : KA2507 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2019
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
Details : KA2507 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2017
Details : KA2237 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 10, 2016
Reset All
